Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02633449Not ApplicableCompleted

Psychotherapy Plus: Combining Cognitive Behavioral Therapy With tDCS

Role: collaborator

NCT02789917Phase 4Completed

APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF

Role: collaborator

NCT00159081Phase 4Completed

One Year Drug Treatment in First-Episode Schizophrenia

Role: collaborator

All 3 trials loaded